{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:07:25Z","timestamp":1791461245426,"version":"4.3.4"},"reference-count":65,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jhepr.2023.100818","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T14:07:02Z","timestamp":1687961222000},"page":"100818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1026-7476","authenticated-orcid":false,"given":"Pietro","family":"Lampertico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9899-4669","authenticated-orcid":false,"given":"Elisabetta","family":"Degasperi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Sandmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cihan","family":"Yurdaydin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Roulot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Zoulim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florin Alexandru","family":"Caruntu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helenie","family":"Kefalakes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Lucifora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosh","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Castera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Rizzetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Cornberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Dandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizia","family":"Brunetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Reau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Gish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo","family":"Aleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarik","family":"Asselah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"de L\u00e9dinghen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2023.100818_bib1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2023.100818_bib2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/gutjnl-2018-316601","article-title":"Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis","volume":"68","author":"Chen","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2023.100818_bib3","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/infdis\/jiz633","article-title":"Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection","volume":"221","author":"Miao","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhepr.2023.100818_bib4","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jhep.2021.01.014","article-title":"The changing context of hepatitis D","volume":"74","author":"Rizzetto","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100818_bib5","unstructured":"https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b."},{"key":"10.1016\/j.jhepr.2023.100818_bib6","unstructured":"https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-d."},{"key":"10.1016\/j.jhepr.2023.100818_bib7","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100818_bib8","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100818_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhepr.2023.100818_bib10","unstructured":"Cordua E, Pisaturo M, Alessio L, Di Fraia A, Macera M, Minichini C, et\u00a0al. Hepatitis D virus infection in a large cohort of immigrants in southern Italy: a multicenter, prospective study. Delta Cure 1st International Meeting, Poster #7. https:\/\/www.deltacure2022.com\/pages\/posterExhibition\/download\/P_07.pdf."},{"key":"10.1016\/j.jhepr.2023.100818_bib11","unstructured":"Lampertico P, Perrone V, Sangiorgi D, Dovizio M, Degli Esposti L, Kim C, et\u00a0al. Evaluating Hepatitis Delta virus disease prevalence, incidence and patient characteristics among adults in Italy in the outpatient setting. Delta Cure 1st International Meeting, Poster#12. https:\/\/www.deltacure2022.com\/pages\/posterExhibition\/download\/P_12.pdf."},{"key":"10.1016\/j.jhepr.2023.100818_bib12","unstructured":"Strzepka J, Bhagwat M, Aloman C. Evaluating screening rates for hepatitis D in hepatitis B patients. Delta Cure 1st International Meeting, Poster #10. https:\/\/www.deltacure2022.com\/pages\/posterExhibition\/download\/P_10.pdf."},{"key":"10.1016\/j.jhepr.2023.100818_bib13","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jhep.2015.04.025","article-title":"Delta hepatitis within the Veterans Affairs medical system in the United States: prevalence, risk factors, and outcomes","volume":"63","author":"Kushner","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100818_bib14","unstructured":"Gish R, Wong R, Kim C, Leung G, Jacobson I, Lim J, et al. Significantly higher clinical and economic burden following diagnosis of Hepatitis D virus infection among U.S. adults with chronic Hepatitis B. Delta Cure 1st International Meeting, Poster #16. https:\/\/www.deltacure2022.com\/pages\/posterExhibition\/download\/P_16.pdf."},{"key":"10.1016\/j.jhepr.2023.100818_bib15","doi-asserted-by":"crossref","unstructured":"Lampertico P, Perrone V, Sangiorgi D, Dovizio M, Degli Esposti L, Kim C, et al. Real-world analysis of healthcare resource utilization and costs among diagnosed Hepatitis D patients within the outpatient setting in Italy. Delta Cure 1st International Meeting. Poster #13. https:\/\/www.deltacure2022.com\/pages\/posterExhibition\/download\/P_13.pdf.","DOI":"10.2147\/PTT.S396003"},{"key":"10.1016\/j.jhepr.2023.100818_bib16","doi-asserted-by":"crossref","unstructured":"Buti M, Kaushik A, Ascanio M, Darba J, Kachru N. Rising clinical and economic burden among chronic Hepatitis D patients who attended Spanish hospitals. Delta Cure 1st International Meeting, Poster #18. https:\/\/www.deltacure2022.com\/pages\/posterExhibition\/download\/P_18.pdf.","DOI":"10.1016\/S0168-8278(22)00939-4"},{"key":"10.1016\/j.jhepr.2023.100818_bib17","unstructured":"Turcanu A, Cumpata V, Cebanu E, Andries L, Pineau P. Demographic features of HDV-infected patients from Republic of Moldova. Delta Cure 1st International Meeting, Poster #10. https:\/\/www.deltacure2022.com\/pages\/posterExhibition\/download\/P_10.pdf."},{"key":"10.1016\/j.jhepr.2023.100818_bib18","doi-asserted-by":"crossref","unstructured":"Rizzo G, Ferraro D, Rancatore G, Graceffa P, Falco G, La Mantia C, et al. The burden of HDV infection: a ten-years\u2019 experience of a Sicilian tertiary centre of liver disease. Delta Cure 1st International Meeting, Poster #15. https:\/\/www.deltacure2022.com\/pages\/posterExhibition\/download\/P_15.pdf.","DOI":"10.1016\/j.dld.2023.01.115"},{"key":"10.1016\/j.jhepr.2023.100818_bib19","unstructured":"Wranke A, Deterding J, Heindrich B, Calle Serrano B, Kirschner J, Bremer B, et al. Clinical long-term outcome of hepatitis delta compared to HBV monoinfection. Delta Cure 1st International Meeting, Poster #6. https:\/\/www.deltacure2022.com\/pages\/posterExhibition\/download\/P_06.pdf."},{"key":"10.1016\/j.jhepr.2023.100818_bib20","unstructured":"Garc\u00eda-Pras E, Leonel T, Rodr\u00edguez-Tajes S, Garcia-Lopez M, Lens S, Marino Z, et al. Innate immune responses and liver damage pathways are highly activated in chronic hepatitis delta. Delta Cure 1st International Meeting, Poster #44. https:\/\/www.deltacure2022.com\/pages\/posterExhibition\/download\/P_44.pdf."},{"key":"10.1016\/j.jhepr.2023.100818_bib21","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/hep.31214","article-title":"Long-term study of hepatitis delta virus infection at secondary care centers: the impact of viremia on liver-related outcomes","volume":"72","author":"Kamal","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100818_bib22","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1053\/j.gastro.2004.03.017","article-title":"Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis","volume":"126","author":"Farci","year":"2004","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.jhepr.2023.100818_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101002","article-title":"Anti-HDV IgM as a marker of disease activity in hepatitis delta","volume":"9","author":"Wranke","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2023.100818_bib24","unstructured":"Gerber A, Brichler S, Dziri S, Alloui C, Brichler S, Le Gal F. Virological diagnosis of Hepatitis Delta Virus infection in France: results of ten years of experience in organizing national quality controls. Delta Cure 1st International Meeting, Poster #1. https:\/\/www.deltacure2022.com\/pages\/posterExhibition\/download\/P_01.pdf."},{"key":"10.1016\/j.jhepr.2023.100818_bib25","unstructured":"Degasperi E, Uceda S, Anolli MP, Borghi M, Sambarino D, Perbellini R, et al. Quantification of serum HDV RNA by Robogene 2.0 in untreated and Bulevirtide-treated HDV patients is significanlty influenced by the extraction methods. Delta Cure 1st International Meeting, Poster #45. https:\/\/www.deltacure2022.com\/pages\/posterExhibition\/download\/P_45.pdf."},{"key":"10.1016\/j.jhepr.2023.100818_bib26","doi-asserted-by":"crossref","unstructured":"Degasperi E, Loglio A, Scholtes C, Uceda Renteria S, Charre C, Facchetti F, et al. Divergent patterns of HBV-RNA AND HBcrAg levels in untreated chronic hepatitis Delta: a large European cross-sectional study. Delta Cure 1st International Meeting, Poster #2. https:\/\/www.deltacure2022.com\/pages\/posterExhibition\/download\/P_02.pdf.","DOI":"10.1016\/j.dld.2022.01.076"},{"key":"10.1016\/j.jhepr.2023.100818_bib27","unstructured":"Salpini R, Piermatteo L, D\u2019Anna S, Gill US, Battisti A, Alkhatib M, et al. HBcrAg tightly correlates with elevated HDV replicative activity and with enhanced liver inflammation and damage: role of HBcrAg as a biomarker of liver disease progression in the setting of HDV co-infection. Delta Cure 1st International Meeting, Poster #5. https:\/\/www.deltacure2022.com\/pages\/posterExhibition\/download\/P_05.pdf."},{"key":"10.1016\/j.jhepr.2023.100818_bib28","unstructured":"Caviglia G, Olivero A, Troshina G, Nicolosi A, Rizzo A, Rizzetto M, et al. HBcrAg to quantitative anti-HBc IgG ratio predicts long-term outcomes in chronic hepatitis D patients. Delta Cure 1st International Meeting, Poster #4. https:\/\/www.deltacure2022.com\/pages\/posterExhibition\/download\/P_04.pdf."},{"key":"10.1016\/j.jhepr.2023.100818_bib29","unstructured":"Sandmann L, Bremer B, Yurdaydin C, Deterding K, Manns M, Cornberg M, et al. HBV RNA levels are associated with virological response to treatment with PEG-IFN in patients with chronic HDV infection. Delta Cure 1st International Meeting, Poster #38. https:\/\/www.deltacure2022.com\/pages\/posterExhibition\/download\/P_38.pdf."},{"key":"10.1016\/j.jhepr.2023.100818_bib30","unstructured":"Food and Drug Administration. Chronic hepatitis D virus infection: developing drugs for treatment guidance for industry. https:\/\/www.fda.gov\/media\/132137\/download."},{"key":"10.1016\/j.jhepr.2023.100818_bib31","article-title":"2019 EASL-AASLD HBV treatment endpoints conference faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - report from the 2019 EASL-AASLD HBV treatment endpoints conference","author":"Cornberg","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100818_bib32","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jhep.2022.05.023","article-title":"Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread","volume":"77","author":"Zhang","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2023.100818_bib33","article-title":"Interferon-based treatment of chronic hepatitis D","author":"Sandmann","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2023.100818_bib34","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ijantimicag.2019.09.012","article-title":"Treatment of chronic hepatitis due to hepatitis B and hepatitis delta virus coinfection","volume":"54","author":"Brancaccio","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jhepr.2023.100818_bib35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1473-3099(22)00318-8","article-title":"Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial","volume":"23","author":"Wedemeyer","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhepr.2023.100818_bib36","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/S0168-8278(20)30651-6","article-title":"48 weeks of high dose (10 mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV\/HDV coinfection","volume":"73","author":"Wedemeyer","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2023.100818_bib37","first-page":"S291","article-title":"Safety and efficacy of bulevirtide monotherapy and in combination with Peginterferon alfa-2a in patients with chronic hepatitis delta: 24-week interim data of MYR204 Phase 2b study","volume":"75","author":"Asselah","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2023.100818_bib38","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.jhep.2022.06.010","article-title":"Bulevirtide with or without pegIFN\u03b1 for patients with compensated chronic hepatitis delta: from clinical trials to real-world studies","volume":"77","author":"Lampertico","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100818_bib39","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa2213429","article-title":"A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D","volume":"389","author":"Wedemeyer","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2023.100818_bib40","doi-asserted-by":"crossref","unstructured":"Lampertico P, Aleman S, Blank A, Bogomolov P, Chulanov V, Mamonova N, et al. Integrated efficacy analysis of 24-week data from two Phase 2 and one Phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose levels for treatment of chronic hepatitis delta. Delta Cure 1st International Meeting, Poster #33. https:\/\/www.deltacure2022.com\/pages\/posterExhibition\/download\/P_33.pdf.","DOI":"10.1016\/S0168-8278(22)01953-5"},{"key":"10.1016\/j.jhepr.2023.100818_bib41","doi-asserted-by":"crossref","unstructured":"Allweiss L, Volmari A, Ladiges Y, Eggers C, Suri V, Wallin J, et al. Strong decline of intrahepatic HDV markers and signs of liver inflammation after 48 weeks of treatment with Bulevirtide in chronic hepatitis D patients: combined intrahepatic results from the clinical trials MYR203 and MYR301. Delta Cure 1st International Meeting, Poster #25. https:\/\/www.deltacure2022.com\/pages\/posterExhibition\/download\/P_25.pdf.","DOI":"10.1055\/s-0042-1760059"},{"key":"10.1016\/j.jhepr.2023.100818_bib42","unstructured":"Lampertico P, Aleman S, Stepanova T, Brunetto MR, Guo Y, Suri V, et al. Treatment with Bulevirtide (BLV) for 48 weeks reduces necroinflammation: results from a histological subset analysis of patients enrolled in studies MYR203 and MYR301. Delta Cure 1st International Meeting, Poster #39. https:\/\/www.deltacure2022.com\/pages\/posterExhibition\/download\/P_39.pdf."},{"key":"10.1016\/j.jhepr.2023.100818_bib43","doi-asserted-by":"crossref","unstructured":"Hollnberger J, Liu Y, Martin R, Manhas M, Aeschbacher T, Chang S, et al. No detectable resistance to bulevirtide in participants with chronic hepatitis D through 24 weeks of treatment. Delta Cure 1st International Meeting. Poster #34. https:\/\/www.deltacure2022.com\/pages\/posterExhibition\/download\/P_34.pdf.","DOI":"10.1016\/S0168-8278(22)01987-0"},{"key":"10.1016\/j.jhepr.2023.100818_bib44","unstructured":"Lampertico P, Aleman S, Asselah T, Cercel-Streinu A, Bogomolov P, Morozov V, et al. Elevations in total serum bile acids with bulevirtide treatment are asymptomatic and not associated with adverse events of interest in patients with chronic hepatitis D. Delta Cure 1st International Meeting, Poster #40. https:\/\/www.deltacure2022.com\/pages\/posterExhibition\/download\/P_40.pdf."},{"key":"10.1016\/j.jhepr.2023.100818_bib45","doi-asserted-by":"crossref","unstructured":"Lampertico P, Aleman S, Asselah T, Bourliere M, Streinu-Cercel A, Bogomolov P, et al. Integrated safety analysis of 24-week data from three Phase 2 and one Phase 3 clinical trials of bulevirtide monotherapy given at 2 mg and 10 mg dose level for treatment of chronic hepatitis delta. Delta Cure 1st International Meeting. Poster #32.. https:\/\/www.deltacure2022.com\/pages\/posterExhibition\/download\/P_32.pdf.","DOI":"10.1016\/S0168-8278(22)01954-7"},{"key":"10.1016\/j.jhepr.2023.100818_bib46","doi-asserted-by":"crossref","unstructured":"Buti M, Wedemeyer H, Aleman S, Chulanov V, Morozov M, Sagalova O, et al. Treatment with bulevirtide improves patient-reported outcomes in patients with chronic hepatitis delta: an exploratory analysis of a Phase 3 trial at 48 weeks. Delta Cure 1st International Meeting, Poster #37. https:\/\/www.deltacure2022.com\/pages\/posterExhibition\/download\/P_37.pdf.","DOI":"10.1055\/s-0042-1760047"},{"key":"10.1016\/j.jhepr.2023.100818_bib47","unstructured":"Dietz-Fricke C, Tacke F, Z\u00f6llner C, Demir M, Schmidt H, Schramm C, et al. Bulevirtide treatment of hepatitis D in Germany: multicentre real-world experience. Delta Cure 1st International Meeting, Poster #22. https:\/\/www.deltacure2022.com\/pages\/posterExhibition\/download\/P_22.pdf."},{"key":"10.1016\/j.jhepr.2023.100818_bib48","doi-asserted-by":"crossref","unstructured":"Deterding K, Xu CJ, Port K, Maasoumy B, Cornberg M, Wedemeyer H. Baseline bile acid levels but not bile acid increases during bulevirtide treatment of hepatitis D are associated with HDV RNA decline. Delta Cure 1st International Meeting, Poster #41. https:\/\/www.deltacure2022.com\/pages\/posterExhibition\/download\/P_41.pdf.","DOI":"10.1016\/S0168-8278(22)02010-4"},{"key":"10.1016\/j.jhepr.2023.100818_bib49","unstructured":"Sandmann L, Tergast TL, Deterding K, Wedemeyer H, Maasoumy B. Improvement of portal hypertension during viral suppression in patients with hepatitis delta - the ImPHrove-D study. Delta Cure 1st International Meeting, Poster #35. https:\/\/www.deltacure2022.com\/pages\/posterExhibition\/download\/P_35.pdf."},{"key":"10.1016\/j.jhepr.2023.100818_bib50","unstructured":"Zoulim F, Fougerou-Leurent C, Gordien E, Scholtes C, Metivier S, de Ledinghen V, et al. Real-life study of bulevirtide in chronic hepatitis Delta: preliminary results of the ANRS I MIE HD EP01 HDV prospective cohort. Delta Cure 1st International Meeting, Poster #36. https:\/\/www.deltacure2022.com\/pages\/posterExhibition\/download\/P_36.pdf."},{"key":"10.1016\/j.jhepr.2023.100818_bib51","doi-asserted-by":"crossref","unstructured":"Degasperi E, Anolli MP, Uceda S, Sambarino D, Borghi M, Perbellini R, et al. Bulevirtide monotherapy in HDV patients with compensated cirrhosis and clinically significant portal hypertension. Delta Cure 1st International Meeting, Poster #19. https:\/\/www.deltacure2022.com\/pages\/posterExhibition\/download\/P_19.pdf.","DOI":"10.1016\/S0168-8278(22)02031-1"},{"key":"10.1016\/j.jhepr.2023.100818_bib52","doi-asserted-by":"crossref","unstructured":"Anolli MP, Degasperi E, Allweiss L, Uceda S, Sambarino D, Borghi M, et al. Cure of Hepatitis Delta infection following 3 years of Bulevirtide monotherapy in a patient with compensated advanced cirrhosis. Delta Cure 1st International Meeting, Poster #20. https:\/\/www.deltacure2022.com\/pages\/posterExhibition\/download\/P_20.pdf.","DOI":"10.1016\/S0168-8278(22)02052-9"},{"key":"10.1016\/j.jhepr.2023.100818_bib53","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/hep.29658","article-title":"Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study","volume":"67","author":"Yurdaydin","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100818_bib54","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/hep.32259","article-title":"A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis","volume":"75","author":"Yurdaydin","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100818_bib55","unstructured":"Yurdaydin C, Yurdcu E, G\u00fcm\u00fc\u015fsoy M, Keskin O, Gencdal G, Akyildiz M, et al. Functional cure with lonafarnib-based therapy in chronic hepatitis delta. Delta Cure 1st International Meeting. Poster #21. https:\/\/www.deltacure2022.com\/pages\/posterExhibition\/download\/P_21.pdf."},{"key":"10.1016\/j.jhepr.2023.100818_bib56","unstructured":"https:\/\/ir.eigerbio.com\/news-releases."},{"key":"10.1016\/j.jhepr.2023.100818_bib57","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jhep.2022.07.010","article-title":"Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB","volume":"77","author":"Yuen","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2023.100818_bib58","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0168-8278(22)00437-8","article-title":"Efficacy and safety of finite 48-week treatment with the siRNA JNJ-3989 and the capsid assembly modulator (CAM-N) JNJ-6379 in HBeAg negative virologically suppressed (VS) chronic hepatitis B (CHB) patients: results from REEF-2 study","volume":"77","author":"Agarwal","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2023.100818_bib59","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04535544."},{"key":"10.1016\/j.jhepr.2023.100818_bib60","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05461170."},{"key":"10.1016\/j.jhepr.2023.100818_bib61","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0168-8278(22)00444-5","article-title":"Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection on stable nucleos (t)ide analogue therapy: interim results from the randomised phase 2b B-Clear study","volume":"77","author":"Yuen","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2023.100818_bib62","doi-asserted-by":"crossref","first-page":"S880","DOI":"10.1016\/S0168-8278(22)02054-2","article-title":"Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection not on stable nucleos (t)ide analogue therapy: interim results from the randomised phase 2b B-Clear study","volume":"77","author":"Lim","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2023.100818_bib63","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2468-1253(17)30288-1","article-title":"Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial","volume":"2","author":"Bazinet","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2023.100818_bib64","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/hep4.1951","article-title":"HBsAg isoform dynamics during NAP-based therapy of HBeAg-negative chronic HBV and HBV\/HDV infection","volume":"6","author":"Bazinet","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2023.100818_bib65","unstructured":"Bourli\u00e8re M, Loustaud-Ratti V, Stern C, Bazinet M, Ali S, Lecomte L, et al. Rescue of cirrhotic HBV\/HDV infection from bulevirtide failure by subcutaneous REP 2139-Mg. Delta Cure 1st International Meeting, Poster #27. https:\/\/www.deltacure2022.com\/pages\/posterExhibition\/download\/P_27.pdf."}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555923001490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555923001490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:31:54Z","timestamp":1762900314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555923001490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":65,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S2589555923001490"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2023.100818","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2023.100818","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100818"}}